New strategy for COVID-19 vaccination: targeting the receptor

Progress of the COVID-19 vaccine effort: viruses, vaccines and

New vaccine may protect against future variants of COVID-19 and

COVID-19 vaccine - Wikipedia

Generation and utility of a single-chain fragment variable monoclonal antibody platform against a baculovirus expressed recombinant receptor binding domain of SARS-CoV-2 spike protein - ScienceDirect

PDF) Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2

Vaccines, Free Full-Text

Issue Information - 2020 - Journal of Neurochemistry - Wiley

An overview of current drugs and prophylactic vaccines for

Targeting Tumor Glycans for Cancer Therapy - Glycopedia

PDF) New strategy for COVID-19 vaccination: targeting the receptor-binding domain of the SARS-CoV-2 spike protein

Vaccination strategies and Therapeutic monoclonal antibodies (mAbs

Researchers develop a nasal vaccine that prevents COVID-19 in

Applications of genetic engineering in COVID-19 - ScienceDirect

PDF) New strategy for COVID-19 vaccination: targeting the receptor-binding domain of the SARS-CoV-2 spike protein

NCI's Research on COVID-19, Vaccines, and Antibodies - NCI